Severe skin reaction in a patient with gastrointestinal stromal tumor treated with imatinib mesylate.
Imatinib mesylate is a selective protein kinase inhibitor, highly active in patients with chronic myeloid leukemia (CML) and gastrointestinal stromal tumors (GISTs). Cutaneous toxicity, a well-recognized, dose-related side-effect of imatinib mesylate, has been reported in 18 to 69% of patients with GIST treated with doses ranging from 400 to 800 mg once a day. In this case-report a severe skin reaction observed in a patient with GIST treated with imatinib mesylate, in an adjuvant setting and whose severity led to definitive drug discontinuation, is described. Therapeutic management and clinical course are illustrated.
Ferraresi
Virginia
V
Department of Medical Oncology A, Regina Elena Cancer Institute, Rome, Italy. ferraresi@ifo.it
Catricalà
Caterina
C
Ciccarese
Mariangela
M
Ferrari
Angela
A
Zeuli
Massimo
M
Cognetti
Francesco
F
D001549:Benzamides; D004890:Erythema / Q000139:chemically induced*; D005260:Female; D046152:Gastrointestinal Stromal Tumors / Q000188:drug therapy*; D006801:Humans; D000068877:Imatinib Mesylate; D008875:Middle Aged; D010879:Piperazines / Q000009:adverse effects* / Q000627:therapeutic use; D011743:Pyrimidines / Q000009:adverse effects* / Q000627:therapeutic use
D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate